American Thoracic Society Quick-Reference GUIDELINES Apps
Issue link: https://eguideline.guidelinecentral.com/i/769839
7 Î In patients with HAP/VAP caused by Acinetobacter species, ATS and IDSA suggest treatment with either a carbapenem or ampicillin/ sulbactam if the isolate is susceptible to these agents (W-L). Î In patients with HAP/VAP caused by Acinetobacter species that is sensitive only to polymyxins, ATS and IDSA recommend intravenous polymyxin (colistin or polymyxin B) (S-L), and ATS and IDSA suggest adjunctive inhaled colistin (W-L). Î In patients with HAP/VAP caused by Acinetobacter species that is sensitive only to colistin, ATS and IDSA suggest NOT using adjunctive rifampicin (W-M). Î In patients with HAP/VAP caused by Acinetobacter species, ATS and IDSA recommend against the use of tigecycline (S-L). Î In patients with HAP/VAP caused by a carbapenem-resistant pathogen that is sensitive only to polymyxins, ATS and IDSA recommend intravenous polymyxins (colistin or polymyxin B) (S-M), and ATS and IDSA suggest adjunctive inhaled colistin (W-L). Î For patients with VAP, ATS and IDSA recommend a 7-day course of antimicrobial therapy rather than a longer duration (S-M). Î For patients with HAP, ATS and IDSA recommend a 7-day course of antimicrobial therapy (S-VL). Î For patients with HAP/VAP, ATS and IDSA suggest that antibiotic therapy be de-escalated rather than fixed (W-VL). Î For patients with HAP/VAP, ATS and IDSA suggest using PCT levels plus clinical criteria to guide the discontinuation of antibiotic therapy, rather than clinical criteria alone (W-L). Î For patients with suspected HAP/VAP, ATS and IDSA suggest NOT using the CPIS to guide the discontinuation of antibiotic therapy (W-L). S, strong ; W, weak strength of recommendation H, high; M, moderate; L, low; VL, very low quality of evidence